New York Top Doctor, Dr. David Samadi Highest Rated Urology Expert

Nationally recognized expert in urology diseases, Dr. David Samadi has helped change the treatment of diseases of the prostate. Samadi uses his SMART surgery technique for the removal of the prostate. This technique combines the benefits of laparoscopic surgery with an assisted robotic arm, and his skilled hands. A four-arm robotic assistant is manually controlled by the surgeon. The movement possibilities of the instruments are modeled by Dr. Samadi’s human hands. A high-performance 3D optics allows the spatial representation of the surgical field in an up to 10-fold magnification. In this surgery, the patient benefits from diminished tissue trauma, earlier urinary continence, a higher recovery rate and an usually fast convalescence. The mobility of the patient is promptly restored after surgery and his return to his daily regimen is correspondingly easier.

Early last year, Republican Presidential Nominee, and Former Governor of Massachusetts, Mitt Romney underwent a successful prostate surgery. According to Dr. David Samadi, early detection and the right approach for treatment will result in restoral of full function. In an interview, published on Huffington Post, Dr. Samadi concluded how prostate surgery is always better than radiation, since patients can be exposed to a secondary cancer with radiation treatment. Mitt Romney chose surgery and successfully beat prostate cancer.Dr. David Samadi is a leading New York Urologist, currently Chief of Robotic Surgery at Lenox Hill Hospital. He received his Bachelor of Arts degree in Biochemistry, as well as his Medical Degree at Stony Brook University in New York. He completed residency training at Montefiore and Albert Einstein Hospitals in New York, and in 2001, a proctology fellowship at Memorial Sloan Kettering Cancer Center.

With more than 21 years as a practicing doctor, Dr. David Samadi is also one of the most celebrated, highest rated, and honored professionals. He’s been named Top Doctor in 2009, 2010, 2011, 2012, 2013; Most Compassionate Doctor from 2010 to 2013, and won Patient Choice Awards from 2008 to 2013. Dr. Samadi is not only interested in the screening and treatment for prostate cancer, but how to treat the disease holistically. On his television show, “Sunday Housecall” he has often referred to health modifications, like dietary concerns, to help diminish the risk of prostate cancer. His show is broadcasts on Sundays at 12:30pm, where invited experts discuss a myriad of health related issues and offer advice.There are many ways to keep up-to-date with Dr. David Samadi and the latest developments on urologic diseases. Follow him on Facebook, or Dr. Samadi TV, or access his YouTube videos.

How Oncotarget is Benefiting Cancer Researchers

Cancer is one of the most researched illnesses. Just like it is the case with other medical studies, researchers often find it hard to publish their findings. This is partly caused by difficulties in finding notable journals to publish these findings in them. Thanks to Oncotarget, cancer researchers have a platform for disseminating information pertaining to oncological research.

Since its establishment in 2010, Oncotarget has established itself as a prominent journal, which mainly focuses on cancer research and oncology. This weekly publication is meant for articles focusing on ongoing oncological research. All articles that are published in the journal are peer reviewed to ensure that they meet academic and scientific standards. The articles are exclusively published in English. Nonetheless, Oncotarget is available globally since it accepts articles and papers from researchers from across the globe.

How the Journal Operates

Oncotarget is the brainchild of renowned researchers, Mikhail Blagosklonny and Andrei V. Gudkov. Both are experienced oncologists and serve as the journal’s co-editors-in-chief besides undertaking their own research. Oncotarget is popular with scientists due to its prominence and meticulous peer review process, which is spearheaded by a competent editorial board comprising of healthcare professionals who are associated with notable institutions.

Oncotarget’s reputation is attested to by the fact that is indexed via Index Medicus/MEDLINE/PubMed, the Science Citation Index Expanded, Scopus, and BIOSIS Previews. In as much as it mainly targets cancer and oncology research, articles that are associated with other related areas are also accepted by the editorial board. Researchers who want their articles published on the journal can easily find information about the submission and peer review process on the publication’s website.

Learn more: http://endnote.com/downloads/style/oncotarget

Oncotarget is itself published by Impact Journals. By virtue of being an open source journal, its articles are available at no fee. This is due to the journal’s dedication towards disseminating free information about cancer research to the medical community. This goes a long way in enhancing ongoing research besides beefing up the existing body of knowledge. Oncotarget also partners with prestigious institutions such as Jon Hopkins, Columbia, and Harvard universities. Its founders work at the Roswell Cancer Institute. This explains why the journal has gained prominence within a relatively short time. Follow Oncotarget journal on Twitter.